Zhaoxia M. Dai

Dalian, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications

NAT10 promotes lung cancer progression by enhancing glutamine metabolism through increasing ac4C modification on NIT2.

NAT10 promotes lung cancer progression by enhancing glutamine metabolism through increasing ac4C modification on NIT2.

Journal: Molecular immunology
Published: November 06, 2025

Reversible ubiquitination regulates HSF1 phase separation in response to proteotoxic stress.

Reversible ubiquitination regulates HSF1 phase separation in response to proteotoxic stress.

Journal: Life sciences
Published: September 15, 2025

KAT2A Deficiency Suppresses Lung Cancer Progression by Downregulating MYC Through Decreasing MYC Succinylation.

KAT2A Deficiency Suppresses Lung Cancer Progression by Downregulating MYC Through Decreasing MYC Succinylation.

Journal: Cancer science
Published: June 18, 2025

Advances in targeting KRAS mutations: A promising approach for the treatment of non‑small cell lung cancer (Review).

Advances in targeting KRAS mutations: A promising approach for the treatment of non‑small cell lung cancer (Review).

Journal: Oncology reports
Published: May 13, 2025

Surgery after induced anti-PD-L1 therapy and chemotherapy for stage I‒III small-cell lung cancer: a phase 2 trial (LungMate-005).

Surgery after induced anti-PD-L1 therapy and chemotherapy for stage I‒III small-cell lung cancer: a phase 2 trial (LungMate-005).

Journal: Cell discovery
Published: February 12, 2025

Periplocin potentiates ferroptotic cell death in non-small cell lung cancer by inducing the degradation of Nrf2.

Periplocin potentiates ferroptotic cell death in non-small cell lung cancer by inducing the degradation of Nrf2.

Journal: Cancer cell international
Published: February 05, 2025

Neoadjuvant Targeted Therapy with Dacomitinib in a Stage IIIA Non-Small-Cell Lung Cancer Patient Harboring EGFR G719X: A Case Report.

Neoadjuvant Targeted Therapy with Dacomitinib in a Stage IIIA Non-Small-Cell Lung Cancer Patient Harboring EGFR G719X: A Case Report.

Journal: OncoTargets and therapy
Published: October 21, 2024

HSP90 inhibition induces oncogenic EGF receptor degradation to suppress cell growth in non-small cell lung cancer.

HSP90 inhibition induces oncogenic EGF receptor degradation to suppress cell growth in non-small cell lung cancer.

Journal: European journal of pharmacology
Published: October 09, 2024

Mechanism and Application Prospects of NLRC3 Regulating cGAS-STING Pathway in Lung Cancer Immunotherapy.

Mechanism and Application Prospects of NLRC3 Regulating cGAS-STING Pathway in Lung Cancer Immunotherapy.

Journal: International journal of medical sciences
Published: August 14, 2024

USP39 phase separates into the nucleolus and drives lung adenocarcinoma progression by promoting GLI1 expression.

USP39 phase separates into the nucleolus and drives lung adenocarcinoma progression by promoting GLI1 expression.

Journal: Cell communication and signaling : CCS
Published: August 11, 2024

Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial.

Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial.

Journal: Nature medicine
Published: June 11, 2024

HSP90: A promising target for NSCLC treatments.

HSP90: A promising target for NSCLC treatments.

Journal: European journal of pharmacology
Published: December 04, 2023
Showing 1-12 of 30

Last Updated: 09/26/2026